MedTrace Logo

Effect of Anti CD20 in Pemphigus Desease

NCT00213512 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2013-06-18

No results posted yet for this study

Summary

to treat in an open non comparative clinical study patients presenting pemphigus with corticodependance, corticoresistance and contre-indication to systemic steroids.

Conditions

  • Pemphigus

Interventions

DRUG

Mabthera

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Principal Investigators

  • pascal Joly, MD-PHD · UH-Rouen

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2006-06-30
Completion
2008-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00213512 on ClinicalTrials.gov